Oppenheimer analyst Leland Gershell initiated coverage of Quince Therapeutics (QNCX) with an Outperform rating and $10 price target ahead of the Phase 3 results in ataxia-telangiectasia, a rare, fatal pediatric neurodegenerative disorder that the firm says lacks approved therapies. The analyst sees a $1B-plus global opportunity for Quince’s lead candidate EryDex and projects $200M in 2031 U.S. sales. Opco says its “enthusiasm” for the drug’s development and commercial success is driven by key opinion leader checks, prior clinical data, and a pivotal design it sees as “heavily derisked.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNCX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue